Retraction: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (Proceedings of the National Academy of Sciences of the United States of America (2014) 111 (E5429-E5438) DOI: 10.1073/pnas.1421438111);Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 50, 2014, Pages E5429-E5438

  Samanta, Debangshu ^a   Gilkesa, Daniele M ^a   Chaturvedia, Pallavi ^a   Xiang, Lisha ^a,b   Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Digoxin; Mammary fat pad implantation; Tumor relapse

Indexed keywords

ACRIFLAVINE; ALDEHYDE DEHYDROGENASE; DIGOXIN; ESTROGEN RECEPTOR; GEMCITABINE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROGESTERONE RECEPTOR; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; SMAD2 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; VASCULOTROPIN A; DEOXYCYTIDINE; HYPOXIA INDUCIBLE FACTOR 1; LUCIFERASE; PRIMER DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SIZE; CANCER STEM CELL; CANCER SURVIVAL; CELL RENEWAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ERADICATION; DNA REPLICATION; DRUG INHIBITION; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IMAGE PROCESSING; KAPLAN MEIER METHOD; METABOLISM; MICROSCOPY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOBLOTTING; INTERLEUKIN-6; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; LUCIFERASES; MICROSCOPY; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84918530536     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2213289119     Document Type: Erratum

References (56)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983-3988.
2. Heddleston JM, et al. (2010) Hypoxia inducible factors in cancer stem cells. Br J Cancer 102(5):789-795.
3. Oskarsson T, Batlle E, Massagué J (2014) Metastatic stem cells: Sources, niches, and vital pathways. Cell Stem Cell 14(3):306-321.
4. Li X, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672-679.
5. Creighton CJ, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820-13825.
6. Bhola NE, et al. (2013) TGF-β inhibition enhances chemotherapy action against triplenegative breast cancer. J Clin Invest 123(3):1348-1358.
7. Dent R, et al. (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429-4434.
8. Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nat Rev Clin Oncol 6(12):718-730.
9. Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121(10):3786-3788.
10. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938-1948.
11. Russnes HG, Navin N, Hicks J, Borresen-Dale AL (2011) Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 121(10):3810-3818.
12. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
13. Prabhakar NR, Semenza GL (2012) Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol Rev 92(3):967-1003.
14. Semenza GL (2013) HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123(9):3664-3671.
15. Gao P, et al. (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12(3):230-238.
16. Unruh A, et al. (2003) The hypoxia-inducible factor-1 innodataalpha is a negative factor for tumor therapy. Oncogene 22(21):3213-3220.
17. Rohwer N, Cramer T (2011) Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14(3):191-201.
18. Comerford KM, et al. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62(12):3387-3394.
19. Pastan I, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42:277-286.
20. Semenza GL (2014) Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol 9:47-71.
21. Gilkes DM, Semenza GL (2013) Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 9(11):1623-1636.
22. Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102(2):428-435.
23. Conley SJ, et al. (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784-2789.
24. Schwab LP, et al. (2012) Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14(1):R6.
25. Cao Y, et al. (2013) Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res 73(20):6230-6242.
26. Zhang H, et al. (2008) Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc Natl Acad Sci USA 105(50):19579-19586.
27. Lee K, et al. (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 106(42):17910-17915.
28. Wong CC, et al. (2012) Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 90(7):803-815.
29. Zhang H, et al. (2012) HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31(14):1757-1770.
30. Ginestier C, et al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555-567.
31. Charafe-Jauffret E, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69(4): 1302-1313.
32. Dontu G, et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17(10):1253-1270.
33. Ponti D, et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65(13):5506-5511.
34. Sansone P, et al. (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117(12): 3988-4002.
35. Ginestier C, et al. (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120(2):485-497.
36. Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108(4):1397-1402.
37. - stem cell-like breast cancer cells in human tumors. J Clin Invest 121(7): 2723-2735.
38. Hartman ZC, et al. (2013) Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73(11):3470-3480.
39. Mimura I, et al. (2012) Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol Cell Biol 32(15):3018-3032.
40. Przanowski P, et al. (2014) The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia. J Mol Med (Berl) 92(3):239-254.
41. Rajput S, Volk-Draper LD, Ran S (2013) TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 12(8):1676-1687.
42. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS (2014) Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells. Oncogene 33(10):1297-1305.
43. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: Bystander effect mediated by reactive oxygen species. Cancer Res 67(8): 3512-3517.
44. Ramanathan B, et al. (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65(18):8455-8460.
45. Parker JS, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167.
46. Chia SK, et al. (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18(16):4465-4472.
47. Goldman M, et al. (2013) The UCSC Cancer Genomics Browser: Update 2013. Nucleic Acids Res 41(Database issue):D949-D954.
48. Györffy B, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725-731.
49. Xiang L, et al. (2014) Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J Mol Med (Berl) 92(2):151-164.
50. Chintala S, et al. (2010) Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α. Cancer Chemother Pharmacol 66(5):899-911.
51. Tiezzi DG, et al. (2013) Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer. Clinics (Sao Paulo) 68(5): 592-598.
52. Tanei T, et al. (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicinbased chemotherapy for breast cancers. Clin Cancer Res 15(12):4234-4241.
53. Lee HE, et al. (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104(11):1730-1738.
54. Semenza GL (2012) Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4):207-214.
55. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use of Laboratory Animals (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85-23.
56. Ringnér M, Fredlund E, Häkkinen J, Borg A˚, Staaf J (2011) GOBO: Gene expressionbased outcome for breast cancer online. PLoS ONE 6(3):e17911.